A MAJOR WEALTH GENERATION OPPORTUNITY IS AHEAD IN ALZHEIMER’S DRUGS
By Nigam Arora & Dr. Natasha Arora
For the first time in two decades, the FDA has approved a new Alzheimer’s drug. The drug is from Biogen (BIIB). There is a great unmet need for Alzheimer’s treatment. Can you imagine investors getting richer by correctly buying the stocks of companies that produce effective Alzheimer’s drugs? Fortunately, The Arora Report subscribers owned the stock of Biogen before the FDA drug approval and are now sitting on nice gains.
Should investors who do not own Biogen stock rush out now to buy the stock of Biogen on the Alzheimer’s drug news? The newly approved Alzheimer’s drug from BIIB is not a slam dunk.… Please click here or the title below to read more.
June 9, 2021